Is Nice shirking its duty of care by blocking the Abiraterone prostate cancer...
This week there has been much media interest in the National Institute for Health and Clinical Excellence (Nice)'s refusal to recommend the drug Abiraterone for use by the NHS. Nice has made this...
View ArticleDid Nice listen to cancer patients when they rejected Abiraterone and Kadycla?
Two of the latest, high-profile decisions by Nice both impact negatively on patients – in England – whose cancer has metastised and who are looking at the end of their lives. Now there will be no...
View Article
More Pages to Explore .....
